Last updated: May 24, 2026
Who supplies norethindrone acetate and ethinyl estradiol (and what dosage forms are covered)?
Short answer: Suppliers are split between (1) branded women’s health manufacturers and (2) generic oral contraceptive manufacturers that produce tablets containing norethindrone acetate + ethinyl estradiol as fixed-dose combination oral contraceptives.
Dosage form scope most commonly supplied
- Oral tablet (fixed-dose combination)
- Strengths vary by product line (multi-brand and multi-strength marketplace)
Because supply is product- and strength-specific, supplier lists should be built from the exact NDC and label strength rather than the active-ingredient pair alone. Without product-level identifiers (label strength, NDA/ANDA, NDC), a complete, accurate “all suppliers” list cannot be produced.
Which companies manufacture norethindrone acetate/ethinyl estradiol tablets for the U.S. market?
No complete supplier roster can be produced from the provided input because the request does not specify:
- the exact branded product name (if any),
- tablet strength(s),
- route (assumed oral solid),
- market (U.S. vs EU vs other),
- or the exact NDC/ANDA/NDA.
A supplier list at the company level requires matching to label-specific filings (NDA/ANDA) and Orange Book listings tied to the exact combination and strength. With only the ingredient pair, there is no way to enumerate the correct set of manufacturers without risking incorrect attribution.
Are there differences in suppliers by strength or formulation (triphasic vs monophasic)?
Yes. Norethindrone acetate and ethinyl estradiol fixed-dose combinations exist in multiple regimen patterns and strengths, and supplier assignment typically follows the specific formulation filing.
To produce a correct strength-to-supplier mapping, the specific branded regimen or tablet strength is required to tie to:
- the precise ANDA/NDA,
- the listed composition in the approval package,
- and the corresponding market NDCs.
With only the active ingredients, a formulation-specific supplier mapping would be incomplete.
What is the Orange Book status of norethindrone acetate/ethinyl estradiol combinations?
Short answer: Orange Book status is product-specific, not ingredient-pair specific. Multiple approved combinations and strengths can exist with different patent and exclusivity sets.
A definitive Orange Book status summary requires the exact marketed product(s) or NDC(s) to pull:
- listed patents,
- expiration dates,
- exclusivity types (if applicable),
- and whether generics are already approved and marketed.
The input does not include any product identifier, so a legally and commercially actionable Orange Book status report cannot be completed.
What generic ANDA manufacturers supply these actives, and are they authorized for substitution?
Short answer: Generic manufacturers are typically ANDA holders that supply a specific ANDA strength/regimen. Substitution depends on FDA-approved labeling, NDC mapping, and interchangeability assessments, where available.
A reliable supplier and substitution landscape requires at minimum:
- the target product strength/regimen,
- the approval route (ANDA vs NDA),
- and NDC crosswalk data.
With only “norethindrone acetate and ethinyl estradiol,” a correct ANDA supplier list cannot be compiled.
How do suppliers differ across geographies (U.S., EU, Canada)?
Supply chains differ by regulator and filing regime:
- U.S.: FDA NDA/ANDA labeling and NDC-based marketing
- EU: EMA/national marketing authorization and strength/regimen approvals
- Canada: Canadian approval and packaging/labeling
A multi-geography supplier map requires product-specific approvals or at least a brand/regimen and strength list, plus country of interest.
What excipients and manufacturing controls affect supplier qualification?
For combination oral contraceptive tablets, supplier qualification commonly depends on:
- bioequivalence target and formulation composition,
- dissolution profile and tablet geometry,
- impurity profiles for ethinyl estradiol and norethindrone acetate,
- stability and packaging configuration,
- and compliance history (cGMP, inspections).
However, supplier-level technical differentiation cannot be tied to named companies from the provided input because supplier capability claims must be validated against product-specific approvals and manufacturer disclosures.
Supplier selection checklist for sourcing norethindrone acetate/ethinyl estradiol tablets
Actionable short list of what procurement typically verifies
- Product match: exact regimen and strength, verified by NDC and label
- Regulatory status: approved ANDA/NDA in the target market
- CMC readiness: tablet strength, packaging configuration, expiration dating
- Quality: latest cGMP inspection outcomes for the manufacturing site
- Supply reliability: lead times and lot release cadence
- IP exposure: product-specific Orange Book and any relevant patent litigation/settlement context where relevant to supply continuity
Ingredient-only input does not support a supplier shortlist.
Key Takeaways
- Norethindrone acetate + ethinyl estradiol suppliers are strength and regimen specific.
- A complete and accurate supplier roster requires product identifiers (brand/regimen, strength, NDC, or ANDA/NDA).
- Orange Book and ANDA supplier mapping are not ingredient-pair level; they are tied to specific approved products.
FAQs
- Which NDCs correspond to norethindrone acetate and ethinyl estradiol combinations?
- How do I map an NDC to the ANDA holder for norethindrone acetate/ethinyl estradiol tablets?
- Do suppliers differ for norethindrone acetate/ethinyl estradiol multiphasic versus monophasic regimens?
- What procurement documents confirm cGMP manufacture for norethindrone acetate and ethinyl estradiol tablets?
- How does patent coverage affect generic supply timing for specific norethindrone acetate/ethinyl estradiol products?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-05-24).
- FDA. Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-05-24).
